How to Reduce Coupling Variability with Luminex Bead Assays

Top 10 tips for a successful coupling process If you’re designing a new multiplex bead-based assay or adding new targets to an existing xMAP® Technology-based assay, the coupling process required to add a protein or an antibody can seem daunting. We’re here to help! While the Luminex custom assay development service can help you with […]

Read More…

xMAP® Technology Users Battle COVID-19 with New Serology Assays

Designed and built by researchers around the world, xMAP® assays shine light on the antibody response to SARS-CoV-2. Our xMAP® Technology empowers researchers to build their own assays quickly, creatively, and effectively. Designed and built by researchers around the world, xMAP® assays shine light on the antibody response to SARS-CoV-2. If you haven’t seen the […]

Read More…

Precision Coupling with Molar Amounts of Protein

Precision coupling is useful for multiplex antibody assays, screening recombinant antibodies, and more! I’ve been getting a lot of requests lately to provide more information on the molar coupling method. If you’ve been wondering how it works, here’s a quick look at how to incorporate molar coupling into your assay development. When coupling whole immunoglobulins […]

Read More…

The Versatility of Multiplex Antibody Titer Assays for COVID-19 and Beyond

The COVID-19 outbreak that began in Wuhan, China in December 2019 was marked by an increase in the number of cases showing pneumonia-like symptoms.1,2 It was not until about a month after the outbreak began that genomic analysis identified a novel coronavirus as the causative agent. With the emergence of new pathogen strains, genomic assays […]

Read More…

Questions to Ask When Choosing a Multiplex Assay Kit

With the COVID-19 pandemic in full swing, many researchers are looking to multiplex assays to evaluate what they call the “cytokine storm.” This refers to the increase in pro-inflammatory cytokines like IL-6 in patients with COVID-19, which is believed to predict disease severity.1 Many of Luminex’s Partners already have multiplex assays available for research use. […]

Read More…

How Luminex Is Supporting Research Partners’ Pandemic Response

Licensed Technologies Group is finding new ways to boost partner programs Here at Luminex, we are working on all fronts to help fight the coronavirus pandemic. The most visible activities have been the launch of new diagnostic tests—namely, the NxTAG® CoV Extended Panel and the ARIES® SARS-CoV-2 Assay—both of which received Emergency Use Authorization from the […]

Read More…

Considerations Regarding RNA Extraction Kits for SARS-CoV-2 Detection

The novel coronavirus disease (COVID-19) pandemic continues to trigger rapid development of molecular diagnostic tests around the world. Nucleic acid amplification-based tests (NAATs)—such as real-time PCR and isothermal amplification—are the gold standard in molecular diagnostic technologies that are being utilized to detect SARS-CoV-2, the COVID-19 disease-causing virus.1 There are two critical and sequential steps that […]

Read More…

Webinar: Mouse Model Analysis Is Better with Multiplexing

Query hundreds of immunoassay targets, even with limited sample volume To make the most of immunology-focused assays using the limited tissue and fluid samples available from mouse models, scientists should consider using xMAP® Technology from Luminex, according to Daniel Braunschweig, Proteomics Field Application Scientist Leader at Bio-Rad Laboratories. That’s the takeaway from a 30-minute webinar […]

Read More…

How to Choose an Assay Development Platform

The Luminex Team knows assay development. Check out some tips from our experts below. If you need to design a new assay, there are several factors you’ll want to consider before selecting the platform you’ll develop it on. Based on our experience, these are the most important: Analyte of interest: Is your assay meant to […]

Read More…

3D Organoid Cultures Offer Clues to Heterogeneous Therapy Response in Cancer Patients

Luminex-powered DigiWest® assays show significant intratumoral differences in response A publication in PLoS Genetics sheds much-needed light on the heterogeneity of drug response within tumors. The scientists used organoid cultures with several analytical tools, including DigiWest protein expression assays, which are based on xMAP® Technology from Luminex. “Heterogeneous pathway activation and drug response modeled in […]

Read More…